Cargando…
Surveillance of anti-SARS-CoV-2 antibodies in plasma pools and in immunoglobulin medicinal products manufactured since 2020 has shown high neutralizing activity against SARS-CoV-2 and current variants
BACKGROUND: Patients with primary and secondary immunodeficiencies have shown an impaired humoral immune response to COVID-19 vaccination. It is therefore of paramount importance to investigate anti-SARS-CoV-2 antibody levels in plasma pools and in immunoglobulin (IgG) products used to treat these p...
Autores principales: | Romero, Carolina, Diez, José María, Gajardo, Rodrigo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203947/ http://dx.doi.org/10.1016/j.clim.2023.109538 |
Ejemplares similares
-
Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products
por: Romero, Carolina, et al.
Publicado: (2021) -
Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products—an update
por: Romero, Carolina, et al.
Publicado: (2022) -
Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins
por: Díez, José María, et al.
Publicado: (2020) -
RSV reemergence in Argentina since the SARS-CoV-2 pandemic
por: Dolores, Acuña, et al.
Publicado: (2022) -
The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies
por: Durdagi, Serdar, et al.
Publicado: (2022)